Chemotherapy plus rituximab for aggressive B-cell lymphoma in kids
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with an aggressive type of B-cell non-Hodgkin lymphoma (like Burkitt, DLBCL, or PMLBL)
- Able to attend follow-up appointments and manage side effects
- Patient or guardian must sign a consent form
- Cancer cells must have the CD20 protein (this will be tested before starting)
- No prior treatment with rituximab
- Not pregnant or breastfeeding, and no history of hepatitis B
- No other current or past cancers, weak immune system, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
This trial tests a combination of medicines (Pola-R-CHP plus a new drug called Sonrotoclax) for newly diagnosed aggressive B-cell lymphoma, especially cases with high BCL-2 protein or double-hit features. The goal is to see if adding Sonrotoclax helps control the cancer better.
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
Hear when a new Mature B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.